Copyright
©2013 Baishideng.
World J Hematol. Aug 6, 2013; 2(3): 89-98
Published online Aug 6, 2013. doi: 10.5315/wjh.v2.i3.89
Published online Aug 6, 2013. doi: 10.5315/wjh.v2.i3.89
Protocol | Drugs | Ref. |
A1 protocol | VBL/PSL | [6] |
JLSG-96 | VCR/AraC/MTX/6MP/PSL | [13] |
Cladribine-based | 2CDA/PSL, 2CDA/AraC | [37-41] |
Clofarabine-based | Clofarabine | [43,44] |
JLSG-special C | VBL/MTX/6MP/PSL | [11] |
Others | AraC alone | [45] |
Molecular targetting | Vemurafenib | [46] |
Bone therapy | Zoledronic acid | [47] |
- Citation: Imashuku S, Shimazaki C, Tojo A, Imamura T, Morimoto A. Management of adult Langerhans cell histiocytosis based on the characteristic clinical features. World J Hematol 2013; 2(3): 89-98
- URL: https://www.wjgnet.com/2218-6204/full/v2/i3/89.htm
- DOI: https://dx.doi.org/10.5315/wjh.v2.i3.89